Inhibrx Biosciences (INBX) Current Assets (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Current Assets for 3 consecutive years, with $132.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Current Assets fell 17.19% year-over-year to $132.8 million; the TTM figure through Dec 2025 stood at $132.8 million (down 17.19% YoY), while the FY2025 annual figure was $132.8 million, down 17.19% from the prior year.
• Current Assets slipped to $132.8 million in Q4 2025 per INBX's latest filing, from $161.4 million in the prior quarter.
• Across five years, Current Assets topped out at $295.4 million in Q4 2023 and bottomed at $132.8 million in Q4 2025.
• Historically, Current Assets has averaged $202.1 million across 3 years, with a median of $200.7 million in 2024.
• Annual changes were most pronounced in 2024 — Current Assets slumped 45.69% — and 2025, when it fell 17.19%.
• Inhibrx Biosciences' Current Assets stood at $295.4 million in 2023, then plunged by 45.69% to $160.4 million in 2024, then dropped by 17.19% to $132.8 million in 2025.
• Business Quant data shows INBX's Current Assets at $132.8 million in Q4 2025, $161.4 million in Q3 2025, and $194.0 million in Q2 2025.